Toll-like receptor 3 is necessary for dsRNA adjuvant effects

Bruno Salaun1, Maude Greutert, Pedro Romero

  • 1Division of Clinical OncoImmunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (CHUV, Lausanne) and Epalinges, Switzerland. bruno.salaun@isrec.unil.ch

Vaccine
|February 7, 2009
PubMed